BioGaia AB (publ) (BIOG-B.ST)
SEK 110.5
(0.82%)
SEK 110.5
(0.82%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 440.9 Million SEK | 21.98% |
| 2022 | 361.45 Million SEK | 42.45% |
| 2021 | 253.73 Million SEK | 11.21% |
| 2020 | 228.15 Million SEK | -5.92% |
| 2019 | 242.51 Million SEK | -12.56% |
| 2018 | 277.35 Million SEK | 18.61% |
| 2017 | 233.83 Million SEK | 17.25% |
| 2016 | 199.43 Million SEK | 31.05% |
| 2015 | 152.18 Million SEK | -22.7% |
| 2014 | 196.88 Million SEK | 141.12% |
| 2013 | 81.65 Million SEK | -80.93% |
| 2012 | 428.07 Million SEK | 314.96% |
| 2011 | 103.15 Million SEK | 83.33% |
| 2010 | 56.27 Million SEK | 17.85% |
| 2009 | 47.74 Million SEK | 84.78% |
| 2008 | 25.84 Million SEK | 190.94% |
| 2007 | 8.88 Million SEK | 417.6% |
| 2006 | 1.71 Million SEK | 108.29% |
| 2005 | -20.69 Million SEK | -171.91% |
| 2004 | 28.78 Million SEK | 6.05% |
| 2003 | 27.14 Million SEK | -29.49% |
| 2002 | 38.49 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 122.6 Million SEK | 37.48% |
| 2024 Q2 | 141.18 Million SEK | 15.16% |
| 2024 Q3 | 41.42 Million SEK | -70.66% |
| 2023 FY | 440.9 Million SEK | 21.98% |
| 2023 Q2 | 95.03 Million SEK | -35.78% |
| 2023 Q1 | 147.99 Million SEK | -2.99% |
| 2023 Q4 | 89.17 Million SEK | -25.4% |
| 2023 Q3 | 119.53 Million SEK | 25.78% |
| 2022 Q2 | 101.3 Million SEK | 6.3% |
| 2022 Q3 | 93.73 Million SEK | -7.47% |
| 2022 FY | 361.45 Million SEK | 42.45% |
| 2022 Q1 | 95.29 Million SEK | 79.5% |
| 2022 Q4 | 152.55 Million SEK | 62.75% |
| 2021 Q4 | 53.09 Million SEK | -20.97% |
| 2021 FY | 253.73 Million SEK | 11.21% |
| 2021 Q1 | 64.24 Million SEK | 41.98% |
| 2021 Q2 | 69.22 Million SEK | 7.75% |
| 2021 Q3 | 67.17 Million SEK | -2.95% |
| 2020 Q4 | 45.25 Million SEK | 67.33% |
| 2020 Q1 | 55.61 Million SEK | -18.33% |
| 2020 Q2 | 100.23 Million SEK | 80.22% |
| 2020 Q3 | 27.04 Million SEK | -73.02% |
| 2020 FY | 228.15 Million SEK | -5.92% |
| 2019 Q3 | 49.45 Million SEK | -37.01% |
| 2019 FY | 242.51 Million SEK | -12.56% |
| 2019 Q1 | 46.43 Million SEK | -38.17% |
| 2019 Q4 | 68.1 Million SEK | 37.72% |
| 2019 Q2 | 78.51 Million SEK | 69.07% |
| 2018 Q2 | 79.9 Million SEK | 42.31% |
| 2018 Q4 | 75.1 Million SEK | 13.47% |
| 2018 FY | 277.35 Million SEK | 18.61% |
| 2018 Q1 | 56.15 Million SEK | -13.23% |
| 2018 Q3 | 66.19 Million SEK | -17.17% |
| 2017 Q1 | 55.82 Million SEK | 20.42% |
| 2017 Q4 | 64.71 Million SEK | 20.66% |
| 2017 Q3 | 53.63 Million SEK | -10.11% |
| 2017 FY | 233.83 Million SEK | 17.25% |
| 2017 Q2 | 59.66 Million SEK | 6.88% |
| 2016 Q4 | 46.35 Million SEK | -4.17% |
| 2016 Q2 | 53.4 Million SEK | 15.76% |
| 2016 Q1 | 46.13 Million SEK | 67.63% |
| 2016 FY | 199.43 Million SEK | 31.05% |
| 2016 Q3 | 48.37 Million SEK | -9.41% |
| 2015 Q1 | 52.57 Million SEK | 72.02% |
| 2015 FY | 152.18 Million SEK | -22.7% |
| 2015 Q4 | 27.52 Million SEK | -7.3% |
| 2015 Q3 | 29.69 Million SEK | -29.98% |
| 2015 Q2 | 42.4 Million SEK | -19.34% |
| 2014 Q2 | 24.93 Million SEK | -79.86% |
| 2014 Q3 | 17.61 Million SEK | -29.37% |
| 2014 Q4 | 30.56 Million SEK | 73.53% |
| 2014 Q1 | 123.77 Million SEK | 420.67% |
| 2014 FY | 196.88 Million SEK | 141.12% |
| 2013 FY | 81.65 Million SEK | -80.93% |
| 2013 Q2 | 26.33 Million SEK | 48.3% |
| 2013 Q4 | 23.77 Million SEK | 72.32% |
| 2013 Q3 | 13.79 Million SEK | -47.6% |
| 2013 Q1 | 17.75 Million SEK | 35.12% |
| 2012 Q4 | 13.13 Million SEK | -2.36% |
| 2012 Q3 | 13.45 Million SEK | -30.62% |
| 2012 Q2 | 19.39 Million SEK | -94.92% |
| 2012 Q1 | 382.08 Million SEK | 1508.22% |
| 2012 FY | 428.07 Million SEK | 314.96% |
| 2011 Q4 | 23.75 Million SEK | 7.47% |
| 2011 Q1 | 23.38 Million SEK | 35.24% |
| 2011 Q2 | 33.9 Million SEK | 45.0% |
| 2011 Q3 | 22.1 Million SEK | -34.8% |
| 2011 FY | 103.15 Million SEK | 83.33% |
| 2010 Q1 | 14.07 Million SEK | 18.35% |
| 2010 Q3 | 8.4 Million SEK | -51.62% |
| 2010 FY | 56.27 Million SEK | 17.85% |
| 2010 Q2 | 17.38 Million SEK | 23.49% |
| 2010 Q4 | 17.29 Million SEK | 105.64% |
| 2009 Q2 | 16.58 Million SEK | 24.13% |
| 2009 Q1 | 13.36 Million SEK | 0.0% |
| 2009 FY | 47.74 Million SEK | 84.78% |
| 2009 Q4 | 11.89 Million SEK | 87.04% |
| 2009 Q3 | 6.35 Million SEK | -61.67% |
| 2008 Q2 | 5.03 Million SEK | 0.0% |
| 2008 FY | 25.84 Million SEK | 190.94% |
| 2007 FY | 8.88 Million SEK | 417.6% |
| 2006 FY | 1.71 Million SEK | 108.29% |
| 2005 FY | -20.69 Million SEK | -171.91% |
| 2004 FY | 28.78 Million SEK | 6.05% |
| 2003 FY | 27.14 Million SEK | -29.49% |
| 2002 FY | 38.49 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | 3427.866% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 1252.342% |
| Enzymatica AB (publ) | -48.06 Million SEK | 1017.375% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 1153.848% |
| Gabather AB (publ) | -9.47 Million SEK | 4753.884% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | 3103.467% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 1705.466% |
| Nanexa AB (publ) | -76.62 Million SEK | 675.411% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | 3231.901% |
| ODI Pharma AB | -1.34 Million SEK | 32963.436% |
| Orexo AB (publ) | -109.5 Million SEK | 502.657% |
| Probi AB (publ) | 11.32 Million SEK | -3794.956% |
| Swedencare AB (publ) | 173.2 Million SEK | -154.566% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 90.53% |
| Toleranzia AB | -7.89 Million SEK | 5687.492% |
| Vivesto AB | -356.71 Million SEK | 223.601% |